Stay updated on Phase 2 NSCLC Platform Study Post-Osimertinib Clinical Trial
Sign up to get notified when there's something new on the Phase 2 NSCLC Platform Study Post-Osimertinib Clinical Trial page.

Latest updates to the Phase 2 NSCLC Platform Study Post-Osimertinib Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedRecruitment status updated to 'No longer looking for participants' and the study record version updated to v3.6.0, replacing the previous v3.5.5.SummaryDifference0.2%

- Check18 days agoChange DetectedThe page now shows a new site revision label (Revision: v3.5.5) replacing the previous one, signaling an internal update to the ClinicalTrials.gov interface without changing the study history data.SummaryDifference0.1%

- Check40 days agoChange DetectedA new revision entry v3.5.4 is added to the study's record history, replacing the previous v3.5.3. This reflects an updated version label for the page rather than substantive changes to the study data.SummaryDifference0.1%

- Check47 days agoChange DetectedVersion 57 was added on 2026-05-01, and the record now shows a QC status of Has Not Concluded. The history presents expanded content areas such as Adverse Events, Outcome Measures, Baseline Characteristics, Participant Flow, Eligibility, Arms and Interventions, Study Design, Study Description, Study Status, and related document sections.SummaryDifference1.0%

- Check61 days agoChange DetectedThe page’s build/release “Revision” indicator was updated from v3.5.2 to v3.5.3, reflecting a maintenance/software version bump rather than a change to the displayed trial record history content.SummaryDifference0.1%

- Check68 days agoChange DetectedThe history now shows Results Submitted and Revision: v3.5.2, replacing No Results Posted and Revision: v3.5.0.SummaryDifference0.1%

Stay in the know with updates to Phase 2 NSCLC Platform Study Post-Osimertinib Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Phase 2 NSCLC Platform Study Post-Osimertinib Clinical Trial page.